Home › Modalities › Cell
Cell (34 companies)
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACET | Adicet Bio | ImmunologyNeurology+2 Rare | 8 | Phase 1 | $28.6M | 8 |
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 10 | Phase 2 | $360M | 10 |
| ANIX | Anixa Biosciences | Oncology | 1 | Phase 1 | $111M | 3 |
| ARTV | Artiva Biotherapeutics | Oncology | 6 | — | $203M | 6 |
| AUTL | Autolus Therapeutics | HematologyImmunology+3 Rare | 12 | Approved | $341M | 12 |
| BEAM | Beam Therapeutics | HematologyMetabolic+1 Rare | 1 | Phase 2 | $2.73B | 6 |
| BCTX | BriaCell Therapeutics | Oncology | 7 | Phase 3 | $34.5M | 8 |
| CABA | Cabaletta Bio | DermatologyImmunology+2 Rare | 8 | Phase 2 | $280M | 8 |
| CAPR | Capricor Therapeutics | Infectious DiseaseNeurology Rare | 1 | NDA Submitted | $523M | 2 |
| RNAC | Cartesian Therapeutics | ImmunologyNeurology+1 Rare | 4 | Phase 3 | $230M | 4 |
| IPSC | Century Therapeutics | ImmunologyMetabolic+1 Rare | 9 | Phase 1 | $304M | 9 |
| COYA | Coya Therapeutics | Neurology Rare | 2 | Phase 2 | $70.1M | 6 |
| FATE | Fate Therapeutics | ImmunologyOncology+1 Rare | 10 | Phase 2 | $224M | 10 |
| FBIO | Fortress Biotech | DermatologyHematology+3 Rare | 1 | Approved | $61.7M | 12 |
| HRMY | Harmony Biosciences | MetabolicNeurology Rare | 3 | Approved | $1.94B | 17 |
| IMTX | Immatics | Oncology | 2 | Phase 3 | $968M | 8 |
| IMMX | Immix Biopharma | Hematology Rare | 1 | Phase 1 | $577M | 1 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 6 | Approved | $9.15B | 16 |
| INAB | IN8bio | ImmunologyOncology | 3 | Phase 1 | $10.0M | 4 |
| INMB | Inmune Bio | Dermatology Rare | 1 | Phase 3 | $35.0M | 1 |
| KAPA | Kairos Pharma | Oncology | 1 | Phase 2 | — | 13 |
| KYTX | Kyverna Therapeutics | ImmunologyNeurology+1 Rare | 7 | NDA Submitted | $302M | 7 |
| LEGN | Legend Biotech | Oncology Rare | 17 | Approved | $4.55B | 17 |
| LCTX | Lineage Cell Therapeutics | MetabolicNeurology+1 Rare | 12 | Phase 2 | $258M | 12 |
| LGVN | Longeveron | CardiovascularMetabolic+1 Rare | 4 | Phase 2 | $5.8M | 4 |
| MRKR | Marker Therapeutics | Oncology | 4 | Phase 1 | $14.8M | 4 |
| MESO | Mesoblast | CardiovascularGI/Hepatology+2 Rare | 5 | Approved | $1.85B | 5 |
| INKT | MiNK Therapeutics | ImmunologyOncology+1 Rare | 8 | Phase 2 | $52.8M | 8 |
| NKTX | Nkarta | ImmunologyNeurology+1 Rare | 8 | Phase 1 | $124M | 8 |
| OCGN | Ocugen | Infectious DiseaseOphthalmology Rare | 1 | Phase 3 | $314M | 12 |
| DTIL | Precision Biosciences | Infectious DiseaseMetabolic+1 Rare | 1 | Phase 1 | $296M | 5 |
| TARA | Protara Therapeutics | DermatologyMetabolic+1 Rare | 2 | Phase 3 | $142M | 3 |
| SANA | Sana Biotechnology | MetabolicOncology | 2 | Phase 1 | $710M | 4 |
| TGTX | Tg Therapeutics | Neurology Rare | 1 | Approved | $9.16B | 6 |
No companies match.